Drug Profile
Research programme: respiratory hypersensitivity immunotherapies - DBV Technologies/Stallergenes Greer plc
Alternative Names: Birch pollen allergen immunotherapy - DBV Technologies/Stallergenes Greer plcLatest Information Update: 23 Mar 2023
Price :
$50
*
At a glance
- Originator DBV Technologies; Stallergenes SA
- Developer DBV Technologies; Stallergenes Greer plc
- Class Allergens; Allergy immunotherapies; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory tract disorders; Tree pollen hypersensitivity
Most Recent Events
- 23 Mar 2023 Discontinued - Preclinical for Tree pollen hypersensitivity in France (Intradermal)
- 23 Mar 2023 Discontinued for Respiratory tract disorders in France (Intradermal)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Tree pollen hypersensitivity in France (Intradermal, Patch)